MARKET

IMNN

IMNN

Imunon Inc
NASDAQ
1.660
+0.050
+3.11%
After Hours: 1.600 -0.06 -3.61% 18:40 09/27 EDT
OPEN
1.640
PREV CLOSE
1.610
HIGH
1.678
LOW
1.580
VOLUME
25.52K
TURNOVER
0
52 WEEK HIGH
15.75
52 WEEK LOW
1.540
MARKET CAP
11.78M
P/E (TTM)
-0.3817
1D
5D
1M
3M
1Y
5Y
Celsion changes name to Imunon (IMNN)
Celsion (NASDAQ:CLSN) <a href="https://seekingalpha.com/pr/18944590-...
Seekingalpha · 09/19 20:36
Celsion Corporation Announces Company Name Change to Imunon, To Trade Under Symbol 'IMNN' Effective As Of Sept. 21
Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of the Company&#39;s business focus and its
Benzinga · 09/19 20:32
Celsion Corporation Announces Company Name Change to Imunon, Inc.
New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, today ...
GlobeNewswire · 09/19 20:30
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
Benzinga · 09/15 22:47
Celsion Completes Enrollment Of The Phase I/II OVATION 2 Study With GEN-1 In Advanced Ovarian Cancer
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion
Benzinga · 09/15 12:36
Celsion Completes Enrollment for Phase 1/2 Trial with GEN-1 in Ovarian Cancer; Shares Rise
Celsion Completes Enrollment for Phase 1/2 Trial with GEN-1 in Ovarian Cancer; Shares Rise
MT Newswires · 09/15 10:59
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wa...
GlobeNewswire · 09/12 22:30
Celsion Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q2, Celsion (NASDAQ:CLSN) posted sales of $125 thousand. Earnings were up 42.31%, but Celsion still reported an overall loss of $6.04 million.
Benzinga · 09/09 14:17
More
About IMNN
Imunon, Inc., formerly Celsion Corporation, is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials. Its lead clinical program GEN-1, a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. GEN-1 works by instructing the body to produce cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. The Company has two platform technologies: TheraPlas platform for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies, and its PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. Its platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices.

Webull offers kinds of Imunon Inc stock information, including NASDAQ:IMNN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMNN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMNN stock methods without spending real money on the virtual paper trading platform.